Aspirin Therapy in Myeloproliferative Neoplasms

Introduction to Aspirin Use

The National Comprehensive Cancer Network recommends that aspirin can be prescribed for patients with thrombocytosis, but the decision depends on whether the thrombocytosis is reactive or due to a myeloproliferative neoplasm, the platelet count level, bleeding risk, and presence of JAK2/CALR mutations 1, 2

For very low-risk essential thrombocythemia patients, observation alone is appropriate, according to the National Comprehensive Cancer Network 1
The National Comprehensive Cancer Network recommends withholding aspirin in low-risk patients with platelet counts >1,000×10⁹/L due to acquired von Willebrand disease risk causing paradoxical bleeding 1
Aspirin 81-100 mg daily is recommended for low-risk patients with JAK2 mutations or cardiovascular risk factors, as retrospective analysis suggests benefit in this subgroup, according to the National Comprehensive Cancer Network 1
Aspirin 81-100 mg daily is recommended for intermediate-risk patients, according to the National Comprehensive Cancer Network 1
Cytoreductive therapy plus aspirin 81-100 mg daily is the standard for high-risk patients, according to the National Comprehensive Cancer Network 1

All polycythemia vera patients require aspirin 81-100 mg daily plus phlebotomy to maintain hematocrit <45%, regardless of risk category, based on the ECLAP study, as recommended by the National Comprehensive Cancer Network and Praxis Medical Insights 1, 2

Plain aspirin 81-100 mg daily should be used, as enteric-coated formulations show poor responsiveness in some essential thrombocythemia patients, according to Praxis Medical Insights 3
Twice-daily aspirin may be considered in carefully selected essential thrombocythemia patients with persistent vasomotor symptoms, as once-daily dosing fails to maintain 24-hour platelet inhibition, according to the National Comprehensive Cancer Network 1
Higher doses of aspirin (>100 mg daily) provide no additional antithrombotic benefit but significantly increase gastrointestinal bleeding risk, as reported in Chest and Praxis Medical Insights 3, 4

Patients with platelet counts >1,000×10⁹/L should be screened for acquired von Willebrand disease before initiating aspirin, according to the National Comprehensive Cancer Network 1
Patients on aspirin therapy should be monitored for bleeding symptoms, particularly in the first 3 months of therapy, as recommended by Praxis Medical Insights 5
Platelet count should be assessed every 3-6 months and cytoreductive therapy adjusted to maintain platelets <1,000×10⁹/L in high-risk patients, according to the National Comprehensive Cancer Network 1